Agreement Concerning Joint Research of Ophthalmic drugAgreement Concerning Joint • April 12th, 2023
March 22,2006—CytoPathfinder, Inc.(headquartered in Tokyo, Shinagawa, Japan, CEO: Yoshiji Fujita) and Santen Pharmaceutical Co., Ltd. (headquartered in Osaka, Japan, President and CEO: Takakazu Morita) announced that they have signed a three-year research agreement to jointly search target molecule for ophthalmology drug discovery and apply CytoPathfinder’s cubic liquid crystal technology to ophthalmic drug formulation.
AGREEMENT CONCERNING JOINT FILING OF AMENDMENT NO. 1 TO SCHEDULE 13DAgreement Concerning Joint • December 9th, 2009 • GenNx360 GVI Acquisition Corp. • Communications equipment, nec
The undersigned, being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party.
AGREEMENT CONCERNING JOINT FILING OF SCHEDULE 13DAgreement Concerning Joint • April 11th, 2008 • Fairfax Financial Holdings LTD/ Can • Fire, marine & casualty insurance
AGREEMENT CONCERNING JOINT FILING OF SCHEDULE 13D, as amendedAgreement Concerning Joint • March 6th, 2019 • Montel S.A.R.L. • Retail-jewelry stores
AGREEMENT CONCERNING JOINT FILING OF SCHEDULE 13D, as amendedAgreement Concerning Joint • December 22nd, 2015 • Montrovest B.V. • Retail-jewelry stores
AGREEMENT CONCERNING JOINT FILING OF SCHEDULE 13DAgreement Concerning Joint • March 13th, 2012 • Giggles N' Hugs, Inc. • Retail-eating & drinking places
AGREEMENT CONCERNING JOINT FILING OF SCHEDULE 13D, as amendedAgreement Concerning Joint • June 6th, 2018 • Montrovest B.V. • Retail-jewelry stores
